Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) has successfully acquired Scanwell Health Inc., a pioneer in smartphone-enabled at-home medical testing. The acquisition aims to enhance BD's digital capabilities for at-home diagnostics, including COVID-19 and other infectious diseases. The BD Veritor™ At-Home COVID-19 Test leverages smartphone technology for accurate result interpretation. Although transaction details were not disclosed, it is anticipated to have an immaterial impact on BD's fiscal 2022 financials. This move underscores BD's commitment to innovative health solutions.

BD (Becton, Dickinson and Company) (NYSE: BDX) has expanded its BD COR™ System with the introduction of the MX instrument, designed for high-throughput molecular testing for infectious diseases, including a new CE-marked assay for sexually transmitted infections. The MX instrument, part of a modular system alongside the PX and GX instruments, can process 1,700 specimens and deliver up to 1,000 results in 24 hours, enhancing laboratory efficiency. The platform automates testing workflows, improving diagnostics for women's health and STIs.

BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.

BD (Becton, Dickinson and Company) announced that the new name for its upcoming spinoff of the Diabetes Care business will be embecta. This independent, publicly-traded company aims to empower those living with diabetes while maintaining a connection to BD's legacy. The spinoff is expected to finalize in the second quarter of 2022. Devdatt Kurdikar will serve as CEO, leading a diverse team focused on innovation and improvement in diabetes care products. The name reflects the company's commitment and heritage, aiming to enhance the quality of life for diabetes patients globally.

BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a leader in treatments for chronic venous insufficiency (CVI). This acquisition enhances BD's portfolio of venous disease technologies, leveraging Venclose's innovative Radio Frequency (RF) ablation system that is designed for efficiency and versatility. CVI affects up to 40% of women and 17% of men in the U.S. The dual heating length of the Venclose System allows multiple vein segments to be ablated with one catheter, potentially reducing post-operative pain for patients. The financial impact of the deal is expected to be immaterial for BD's fiscal 2022.

BD (Becton, Dickinson and Company) (NYSE: BDX) issued a statement confirming the effectiveness of its rapid antigen and PCR tests for detecting the COVID-19 Omicron variant. Conducting an analysis based on genome sequences up to Nov. 29, 2021, BD remains confident that its testing methods will identify this new variant. To date, the company has evaluated over 3.5 million SARS-CoV-2 genomes and reported no undetectable variants. BD emphasizes the importance of reliable testing in combating COVID-19's spread and will continue rigorous performance monitoring.

BD (Becton, Dickinson and Company) has appointed Dr. Joseph M. Smith as the new senior vice president and chief scientific officer, effective November 29, 2021. In this role, Smith will oversee external innovation and the technology roadmap for BD, focusing on the future of healthcare, including smart connected care and chronic disease management. He has over 30 years of experience in digital health, previously serving as CEO of Digital Health Corp. Smith holds multiple advanced degrees and has authored numerous publications while holding several patents.

BD (Becton, Dickinson and Company) has appointed Francesca DeMartino as senior vice president of investor relations, effective Nov. 29. DeMartino will oversee the communication of the BD2025 strategy to investors, focusing on shareholder value. She brings over 20 years of experience in investor relations from notable companies, including Medtronic, where her team won awards for investor relations. DeMartino succeeds Kristen Stewart, who moves to a new role within the company.